Colgate-Palmolive Company

NYSE:CL Stok Raporu

Piyasa değeri: US$76.3b

Colgate-Palmolive Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Colgate-Palmolive has a total shareholder equity of $836.0M and total debt of $8.4B, which brings its debt-to-equity ratio to 1009.1%. Its total assets and total liabilities are $16.8B and $15.9B respectively. Colgate-Palmolive's EBIT is $4.3B making its interest coverage ratio 18.1. It has cash and short-term investments of $1.5B.

Anahtar bilgiler

1,009.1%

Borç/özkaynak oranı

US$8.44b

Borç

Faiz karşılama oranı18.1x
NakitUS$1.49b
EşitlikUS$836.00m
Toplam yükümlülüklerUS$15.94b
Toplam varlıklarUS$16.77b

Son finansal sağlık güncellemeleri

Recent updates

If EPS Growth Is Important To You, Colgate-Palmolive (NYSE:CL) Presents An Opportunity

Oct 26
If EPS Growth Is Important To You, Colgate-Palmolive (NYSE:CL) Presents An Opportunity

Colgate-Palmolive Q3: Great Company, But Not Enough To Warrant A Position Now

Oct 25

Colgate-Palmolive: Very Close To A Buy Following Recent Pullback

Oct 17

Colgate-Palmolive: Share Price Returns Should Moderate (Rating Downgrade)

Sep 30

These 4 Measures Indicate That Colgate-Palmolive (NYSE:CL) Is Using Debt Reasonably Well

Sep 11
These 4 Measures Indicate That Colgate-Palmolive (NYSE:CL) Is Using Debt Reasonably Well

Returns At Colgate-Palmolive (NYSE:CL) Appear To Be Weighed Down

Aug 27
Returns At Colgate-Palmolive (NYSE:CL) Appear To Be Weighed Down

Colgate-Palmolive: Stability Pillar Reached Its Fair Value

Aug 19

An Intrinsic Calculation For Colgate-Palmolive Company (NYSE:CL) Suggests It's 31% Undervalued

Aug 12
An Intrinsic Calculation For Colgate-Palmolive Company (NYSE:CL) Suggests It's 31% Undervalued

Colgate-Palmolive: Good Growth Prospects Ahead

Aug 06

Earnings Not Telling The Story For Colgate-Palmolive Company (NYSE:CL)

Jul 11
Earnings Not Telling The Story For Colgate-Palmolive Company (NYSE:CL)

Colgate-Palmolive: Three Items To Look For In The Upcoming Earnings

Jul 10

Colgate-Palmolive: Gladly Holding, Yet Currently Not Buying An All Time Favorite

Jun 23

Does Colgate-Palmolive (NYSE:CL) Have A Healthy Balance Sheet?

Jun 06
Does Colgate-Palmolive (NYSE:CL) Have A Healthy Balance Sheet?

Many Would Be Envious Of Colgate-Palmolive's (NYSE:CL) Excellent Returns On Capital

May 21
Many Would Be Envious Of Colgate-Palmolive's (NYSE:CL) Excellent Returns On Capital

Analysts Have Made A Financial Statement On Colgate-Palmolive Company's (NYSE:CL) First-Quarter Report

Apr 30
Analysts Have Made A Financial Statement On Colgate-Palmolive Company's (NYSE:CL) First-Quarter Report

Colgate-Palmolive: Loading Up Ahead Of Earnings

Apr 16

Why Investors Shouldn't Be Surprised By Colgate-Palmolive Company's (NYSE:CL) P/E

Apr 02
Why Investors Shouldn't Be Surprised By Colgate-Palmolive Company's (NYSE:CL) P/E

Colgate-Palmolive's (NYSE:CL) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 18
Colgate-Palmolive's (NYSE:CL) Shareholders Will Receive A Bigger Dividend Than Last Year

Is Colgate-Palmolive Company (NYSE:CL) Trading At A 33% Discount?

Feb 14
Is Colgate-Palmolive Company (NYSE:CL) Trading At A 33% Discount?

Colgate-Palmolive: I'm Buying Before Interest Rates Decrease

Feb 14

Colgate-Palmolive: Brushing Up Profits In Q4 2023

Jan 30

Is Colgate-Palmolive (NYSE:CL) A Risky Investment?

Jan 19
Is Colgate-Palmolive (NYSE:CL) A Risky Investment?

Getting In Cheap On Colgate-Palmolive Company (NYSE:CL) Might Be Difficult

Jan 01
Getting In Cheap On Colgate-Palmolive Company (NYSE:CL) Might Be Difficult

Colgate-Palmolive: A Better Year Ahead (Rating Upgrade)

Dec 20

Colgate-Palmolive Stock And Its Real Value

Nov 29

Brush Up With Colgate-Palmolive Stock As Earnings Growth Drips On

Nov 14

Colgate-Palmolive (NYSE:CL) Will Want To Turn Around Its Return Trends

Nov 06
Colgate-Palmolive (NYSE:CL) Will Want To Turn Around Its Return Trends

Colgate-Palmolive: Own This Dividend King At The Right Price

Oct 31

Why Colgate-Palmolive Is A Bargain You Shouldn't Ignore Right Now

Oct 13

Does Colgate-Palmolive (NYSE:CL) Have A Healthy Balance Sheet?

Oct 02
Does Colgate-Palmolive (NYSE:CL) Have A Healthy Balance Sheet?

Colgate-Palmolive: Dividend King With Limited Growth

Sep 27

An Intrinsic Calculation For Colgate-Palmolive Company (NYSE:CL) Suggests It's 34% Undervalued

Sep 11
An Intrinsic Calculation For Colgate-Palmolive Company (NYSE:CL) Suggests It's 34% Undervalued

Colgate-Palmolive: Improving Prospects And A Reasonable Valuation

Sep 09

Colgate-Palmolive: A Healthy 7% Return With A Safe Dividend For Investors In A Post-Pandemic World

Aug 16

Colgate And The Importance Of Sales Growth, Expectations Matter

Aug 09

Colgate-Palmolive's (NYSE:CL) Returns On Capital Not Reflecting Well On The Business

Aug 03
Colgate-Palmolive's (NYSE:CL) Returns On Capital Not Reflecting Well On The Business

Colgate-Palmolive: Challenging Growth Prospects

Jul 10

Colgate-Palmolive (NYSE:CL) Is Increasing Its Dividend To $0.48

Jun 27
Colgate-Palmolive (NYSE:CL) Is Increasing Its Dividend To $0.48

Colgate-Palmolive (NYSE:CL) Will Pay A Larger Dividend Than Last Year At $0.48

Jun 13
Colgate-Palmolive (NYSE:CL) Will Pay A Larger Dividend Than Last Year At $0.48

Colgate-Palmolive: The Reasons We Are Becoming More Cautious

Jun 05

Here's Why Colgate-Palmolive (NYSE:CL) Can Manage Its Debt Responsibly

Jun 05
Here's Why Colgate-Palmolive (NYSE:CL) Can Manage Its Debt Responsibly

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CL's short term assets ($5.8B) exceed its short term liabilities ($5.6B).

Uzun Vadeli Yükümlülükler: CL's short term assets ($5.8B) do not cover its long term liabilities ($10.4B).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CL's net debt to equity ratio (830.4%) is considered high.

Borcun Azaltılması: CL's debt to equity ratio has reduced from 4684.5% to 1009.1% over the past 5 years.

Borç Kapsamı: CL's debt is well covered by operating cash flow (47.1%).

Faiz Kapsamı: CL's interest payments on its debt are well covered by EBIT (18.1x coverage).


Bilanço


Sağlıklı şirketleri keşfedin